This is why I’m long term with Avacta14 Apr 2021 14:45
Cancer side will blow Covid side away....
Interview with Carol Greenlees, Head of Clinical Operations
What excites you about the technology and platforms at Avacta?
In the case of the pre|CISION™ platform, one of the major issues with chemotherapy is toxicity. By utilizing FAP activation as a selective drug delivery mechanism, the pre|CISION™ platform provides the capability to deliver chemotherapies to the tumour microenvironment whilst limiting toxicities in non-target tissues which have typically have been limiting factors in the use of these agents. If successful, the pre|CISION™ platform has the capacity to optimise the utilisation of many chemotherapies and immuno-oncology agents that have been mainstays in cancer treatment but have had their utility restricted by dose limiting toxicities.
The Affimer® technology, as a potential novel class of biotherapeutics based on the naturally occurring human protein, Stefin A, that may ultimately extend the benefits of cancer immunotherapies to more patients, is an exciting innovation. Being part of such a development program as it ultimately moves towards the clinic and potentially brings significant benefit to patients is highly motivating.